Abigail D. Jeong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abigail D. Jeong has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin G. Bitler
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
83 shared publications - Courtney A. Bailey
Biomedical Engineering Program University of Colorado Boulder Boulder Colorado USA
83 shared publications - Edward B. Chuong
University of Colorado Boulder
83 shared publications - Elizabeth R. Woodruff
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado
83 shared publications - Francis To
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado
83 shared publications - Kian Behbakht
Department of OB/GYN, The University of Colorado Anschutz Medical Campus, Aurora, Colorado
83 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Figure S2 shows the transcriptional changes of transposable elements via volcano plot due to the treatment of single treatments and combination treatments. It also shows the chromatin profiling of EHMT2 bound to LTR8B elements in the genome after single and combination treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Figure S2 shows the transcriptional changes of transposable elements via volcano plot due to the treatment of single treatments and combination treatments. It also shows the chromatin profiling of EHMT2 bound to LTR8B elements in the genome after single and combination treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-OR cells compared to ID8 cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-OR cells compared to ID8 cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Table S3 shows the antibody panels for the multispectral immunohistochemistry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Table S3 shows the antibody panels for the multispectral immunohistochemistry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to UNC0642 alone.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Figure S1 shows the EHMT-inhibition mediated loss of H3K9Me2 in the different HGSC models. It also shows the transcriptional changes via volcano plot and pathway analysis due to the treatment of single treatments and combination treatments.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Figure S1 shows the EHMT-inhibition mediated loss of H3K9Me2 in the different HGSC models. It also shows the transcriptional changes via volcano plot and pathway analysis due to the treatment of single treatments and combination treatments.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to Olaparib alone.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways negatively enriched in ID8-R cells treated with combinatory UNC0642/Olaparib compared to Olaparib alone.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Figure S4 shows the in vivo model of HGS2 olaparib-resistant cells at day 0 and day 14 of treatment. It also shows mouse weight over the course of the treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Figure S4 shows the in vivo model of HGS2 olaparib-resistant cells at day 0 and day 14 of treatment. It also shows mouse weight over the course of the treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to DMSO control.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell–Dependent Manner
Hallmark pathways enriched in ID8-R cells treated with combinatory EZM8266/Olaparib compared to DMSO control.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Table S4 shows the quantitative PCR primer sequences.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
Supplementary Table S4 shows the quantitative PCR primer sequences.